GNPX Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Genprex Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerGNPX

Market Cap7.9M

Cash RunwayRunway > 12 months

Next Catalyst2028-03

Public Research Snapshot

Genprex Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for COVID-19 in pulmonary inflammation triggered by COVID-19 (Approved).

Pipeline

Asset	Indication	Modality	Stage	Public Note
AVA6000	n/a	n/a	Phase 3	Public pipeline row
Manufacturing	mesenchymal stem cell therapy	Cell Therapy	n/a	Public pipeline row
Contracts	n/a	Vaccine	n/a	Public pipeline row
AFTX-201	n/a	n/a	n/a	Public pipeline row
CD33	n/a	n/a	n/a	Public pipeline row
SGT-003	its gene therapy candidate for Duchenne muscular dystrophy (Duchenne), SGT-003	Gene Therapy	n/a	Public pipeline row
SBP-9330	n/a	n/a	n/a	Public pipeline row
No data found	neuro conditions By PBR Staff Writer Augustine Therapeutics has secured	n/a	Phase 1/2	Public pipeline row

Catalyst Preview

Catalyst	Timing	Asset	Confidence
Clinical Trial Completion	2028-03	quaratusugene ozeplasmid	Low
IND Filing	Nov 2021	AVA6000	Low
Enrollment Update	Dec 2020	COVID-19	Low

Cash Runway Preview

Estimated cash runway: Runway > 12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT01455389	Phase 1 \| Phase 2	TERMINATED	25	2016-10-27
NCT05062980	Phase 1 \| Phase 2	TERMINATED	5	2025-02-03
NCT05703971	Phase 1 \| Phase 2	RECRUITING	62	2026-02
NCT04486833	Phase 1 \| Phase 2	RECRUITING	158	2028-03

Scientific Context

asset_name | AFTX-201
indication | AFTX-201 By Salong Debbarma Affinia Therapeutics has received the US Food and Drug Administration (FDA) fast track design
asset_name | AVA6000
catalyst_type | IND Filing
catalyst_window | Nov 2021

Want the full GNPX research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.